[
  {
    "company_id": "compA_001",
    "company_name": "PharmaNova",
    "molecules": [
      {
        "drug_name": "NovaCure-101",
        "ndc_code": "101010",
        "for_sale_status": "sold",
        "asset_type": "molecule",
        "deal_value": {
          "min": 50,
          "max": 200
        },
        "phenotype": {
          "stage": "Phase 2",
          "therapeutic_area": "Oncology",
          "indication": "Lung Cancer",
          "moa": "EGFR Inhibitor",
          "route": "Oral",
          "modality": "Small Molecule",
          "patent_expiry": 2029
        },
        "company": {
          "type": "Pharma",
          "development_stage": "Clinical",
          "hq": "USA",
          "financial_status": "Growing",
          "partner_status": "Partnered",
          "territory": "Global"
        },
        "sales": {
          "1yr": 60,
          "5yr": 200,
          "peak": 250
        }
      },
      {
        "drug_name": "NovaThera-202",
        "ndc_code": "202020",
        "for_sale_status": "for_purchase",
        "asset_type": "platform",
        "deal_value": {
          "min": 100,
          "max": 300
        },
        "phenotype": {
          "stage": "Preclinical",
          "therapeutic_area": "Neurology",
          "indication": "Alzheimer's",
          "moa": "Beta-Amyloid Inhibitor",
          "route": "IV",
          "modality": "Biologic",
          "patent_expiry": 2035
        },
        "company": {
          "type": "Biotech",
          "development_stage": "Research",
          "hq": "Germany",
          "financial_status": "Stable",
          "partner_status": "Unpartnered",
          "territory": "EU"
        },
        "sales": {
          "1yr": 10,
          "5yr": 80,
          "peak": 120
        }
      }
    ]
  },
  {
    "company_id": "compB_002",
    "company_name": "MediCorp",
    "molecules": [
      {
        "drug_name": "MediBlock-Alpha",
        "ndc_code": "303030",
        "for_sale_status": "all",
        "asset_type": "molecule",
        "deal_value": {
          "min": 20,
          "max": 90
        },
        "phenotype": {
          "stage": "Phase 1",
          "therapeutic_area": "Cardiology",
          "indication": "Arrhythmia",
          "moa": "Ion Channel Modulator",
          "route": "Oral",
          "modality": "Small Molecule",
          "patent_expiry": 2032
        },
        "company": {
          "type": "Pharma",
          "development_stage": "Clinical",
          "hq": "India",
          "financial_status": "Expanding",
          "partner_status": "Partnered",
          "territory": "Asia"
        },
        "sales": {
          "1yr": 35,
          "5yr": 150,
          "peak": 190
        }
      }
    ]
  }
]